Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Rev. méd. Chile ; 144(9): 1112-1118, set. 2016. graf, tab
Article Dans Espagnol | LILACS | ID: biblio-830619

Résumé

Background: The intensity of conditioning chemotherapy and radiotherapy in hematopoietic stem cell transplantation (HSCT) varies according to several factors including the patient’s age, pre-existing conditions and performance status. Myeloablative conditioning (MA) increases transplant related mortality and reduces survival in older patients. Reduced intensity conditioning (RIC) is a good option for these patients. Aim: To report our experience with HSCT in patients of different ages with acute leukemia. Material and Methods: Retrospective analysis of 115 allogeneic HSCT performed in patients with acute myeloid or lymphoblastic leukemia. Results: We analyzed the cohort of patients in groups according to age at transplantation: younger than 40 years (n = 74), 41 to 50 years (n = 25) and older than 51 years of age (n = 16). Overall survival (OS), Disease free survival (DFS) and relapse at five years were similar in both groups of patients younger than 50 years (OS 40 and 44% respectively, DFS 38 and 42% respectively and relapse 40% and 34% respectively, p = NS). Patients over 51 years had a five years OS of 12%. However when we analyzed those patients by date and conditioning we found that patients who were treated with MA regimens in the first decade of the transplant program (before 2000) had lower OS compared to those treated after 2000 with RIC (five years OS 49% and 12% respectively, p < 0.01). No significant differences in terms of OS, recurrence or incidence of graft-versus-host disease were found when comparing groups under 40 years, between 41 and 50 years and older than 51 years treated only with RIC. Conclusions: RIC provides the possibility of HSCT in older patients with rates comparable to those obtained in younger patients successfully treated with MA conditioning.


Sujets)
Humains , Mâle , Femelle , Adolescent , Adulte , Adulte d'âge moyen , Jeune adulte , Leucémie aigüe myélomonocytaire/chirurgie , Transplantation de cellules souches hématopoïétiques/méthodes , Conditionnement pour greffe/méthodes , Leucémie-lymphome lymphoblastique à précurseurs B et T/chirurgie , Récidive , Transplantation homologue/méthodes , Transplantation homologue/mortalité , Analyse de survie , Études rétrospectives , Facteurs âges , Transplantation de cellules souches hématopoïétiques/mortalité , Survie sans rechute , Conditionnement pour greffe/mortalité
2.
Rev. invest. clín ; 57(2): 291-297, mar.-abr. 2005. tab
Article Dans Espagnol | LILACS | ID: lil-632483

Résumé

The feasibility of applying allogeneic cell -mediated therapy in conjunction with allogeneic hematopoietic cell transplantation following reduced -intensity conditioning, with minimal toxicity and no serious transplant-related complications, makes it possible to perform such procedures on an outpatient basis as well to offer a valid option for cure to elderly individuals and patients with less than optimal performance status. Based on available experience, clinical application of this innovative therapy may open new horizons for the treatment of patients with leukemia, lymphoma, myeloma and other diseases. Many patients can now benefit from the advantages of immunotherapy mediated by alloreactive donor lymphocytes, while minimizing transplant-related toxicity and mortality. This kind of transplant is making real progress in the world of transplantation.


El trasplante alogénico no mieloablativo basa su efecto en la capacidad de los linfocitos del donador de erradicar a la enfermedad residual del paciente. El empleo de dosis reducidas de intensidad de radioterapia y/o quimioterapia permite su empleo en pacientes de edad avanzada y aún con comorbilidad. La poca toxicidad del procedimiento evita frecuentemente la hospitalización del paciente, se asocia a menor frecuencia de infecciones y de transfusiones, por ello el costo es sensiblemente menor e ideal para países pobres. Se ha utilizado con éxito desde hace ocho años y en nuestro país su aplicación es cada vez más frecuente. La utilidad principal se ha observado en leucemias crónicas y linfomas indolentes. En leucemia aguda mieloblástica en primera remisión también es útil, siendo menos efectivo en la leucemia aguda linfoblástica y los linfomas no-Hodgkin agresivos. También puede ser utilizado en niños y en pacientes con enfermedades benignas. El trasplante no-mieloablativo es una realidad en el área de los trasplantes.


Sujets)
Adolescent , Adulte , Enfant , Femelle , Humains , Mâle , Transplantation de cellules souches hématopoïétiques , Conditionnement pour greffe/méthodes , Essais cliniques comme sujet , Transplantation de cellules souches de sang du cordon , Prévision , Maladie du greffon contre l'hôte/immunologie , Maladie du greffon contre l'hôte/prévention et contrôle , Hémopathies/chirurgie , Tumeurs hématologiques/chirurgie , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation de cellules souches hématopoïétiques/statistiques et données numériques , Mexique , Chimère obtenue par transplantation , Transplantation homologue , Résultat thérapeutique , Conditionnement pour greffe/mortalité , Conditionnement pour greffe/statistiques et données numériques
SÉLECTION CITATIONS
Détails de la recherche